Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label exploratory tofacitinib mucosal study in moderate to severe ulcerative colitis
NL-OMON47601Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Amsterdam University Medical Center. Primary endpoint: Median change in histological inflammatory infiltrates at week 8. Started Jan 2018; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47601.